Company news

Entera Bio Ltd. news in 2022

Entera Bio Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

November 9, 2022

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

October 5, 2022

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613’s Potential Impact on Wednesday, September 28th @ 10am ET

September 20, 2022

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 11, 2022

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

September 11, 2022

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

August 10, 2022

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

July 25, 2022

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

July 17, 2022

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities

June 16, 2022

Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy

May 15, 2022

Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights

May 11, 2022

Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics

May 4, 2022

Entera Bio to Report First Quarter 2022 Financial Results on May 12

April 27, 2022

Entera Bio to Present at 2022 Maxim Virtual Growth Conference

March 21, 2022

Entera Bio to Present at Aegis Virtual Conference on February 23rd

February 16, 2022

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

January 3, 2022

Calls in 2022

Decks in 2022